Close

Cookies on this website

We use cookies to ensure that we give you the best experience on our website. By continuing to browse this site, you are agreeing to our use of cookies.

Continue Find out more

23 Feb 2009
Director/PDMR Shareholding

Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announces that on February 20, 2009 the following Persons Discharging Managerial Responsibility (“PDMRs”) were granted awards under the Shire Portfolio Share Plan (the “Plan”).

Awards of Stock Settled Appreciation Rights (“SARs”) under Part A of the Plan

Name of PDMR

Type of Security

No Ordinary Shares or ADSsExercise price
Angus Russell (Executive Director)*Ordinary Shares295,580£8.83
Graham Hetherington (Executive Director)*Ordinary Shares100,000£8.83
Tatjana MayOrdinary Shares40,000£8.83
Joseph RusOrdinary Shares30,000£8.83
Michael ColaADSs20,000$38.63
Sylvie GregoireADSs20,000$38.63
Barbara DeptulaADSs12,000$38.63
Anita GrahamADSs12,000$38.63

*Awards to Executive Directors are subject to performance targets

SARs will normally vest after three years, subject to any performance targets. Once vested, SARs will be capable of exercise for a period of two years. No consideration was paid for the grant of the SARs.

Performance Share Awards (“PSA Awards”) under Part B of the Plan

Name of PDMRType of SecurityNo Ordinary Shares or ADSsExercise price
Angus Russell (Executive Director)*Ordinary Shares221,685£8.83
Graham Hetherington (Executive Director)*Ordinary Shares75,000£8.83
Tatjana MayOrdinary Shares30,000£8.83
Joseph RusOrdinary Shares20,000£8.83
Michael ColaADSs15,000$38.63
Sylvie GregoireADSs15,000$38.63
Barbara DeptulaADSs9,000$38.63
Anita GrahamADSs9,000$38.63

*Awards to Executive Directors are subject to performance targets

The PSA awards will normally vest after three years, subject to any performance targets. Once vested, sufficient ordinary shares or ADSs will be transferred or allotted to the participant within 30 days. No consideration was paid for the grant of the PSA awards.This notification is to satisfy the Company's obligations under 3.1.4(R)(1)(a) of the Disclosure and Transparency Rules.

Tony Guthrie
Deputy Company Secretary

For further information please contact:

Investor Relations
Cléa Rosenfeld (Rest of the World) +44 1256 894 160
Eric Rojas (North America) +1 617 551 9715

Notes to editors

SHIRE PLC

Shire’s strategic goal is to become the leading specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit hyperactivity disorder (ADHD), human genetic therapies (HGT) and gastrointestinal (GI) diseases as well as opportunities in other therapeutic areas to the extent they arise through acquisitions. Shire’s in-licensing, merger and acquisition efforts are focused on products in specialist markets with strong intellectual property protection and global rights. Shire believes that a carefully selected and balanced portfolio of products with strategically aligned and relatively small-scale sales forces will deliver strong results.

For further information on Shire, please visit the Company’s website: www.shire.com.

23 Feb 2009 Director/PDMR Shareholding (20KB PDF)

« Back to Shire news

Did you know...

You can sign up to receive email and SMS alerts so that you can keep up to speed with our latest news.

Email and SMS alerts

Did you know...

We donated over $35,000 in
outdated laboratory
equipment
to local
schools?